Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Russia Plague Lab WHO Report: No Spread Found, 5,500 Tests
The Russia plague lab WHO report finds no evidence of spread after a lab worker’s death in Irkutsk; cause remains undetermined. Key findings.
How to Know If You Were Exposed to Measles: 6 Key Steps
Think you were exposed to measles? Learn the signs of exposure, symptom timeline, immunity checks and steps to take, from CDC and WHO guidance.
Largest Measles Outbreak in Decades: Pennsylvania Tops 1,000
Pennsylvania’s outbreak is the largest measles outbreak in decades for a US state, with over 1,000 cases. How it compares, deaths and vaccine uptake.
US Measles Cases Top 4,000 in 45 States: Worst Since 1991
US measles cases passed 4,000 in 2026, with infections in 45 states and DC, CDC data show. The numbers, the hotspots and what the data cannot say.
340B Drug Pricing Program Lawsuit: $1B Cost Fight Revealed
The 340B Drug Pricing Program lawsuit by the AHA targets a federal rebate model that hospitals say would add over $1 billion a year in costs.
Hovilpri FDA Approval: 63% Healing Rate Revealed
Hovilpri FDA approval gives immunocompromised adults an oral option for HSV lesions that resist standard antivirals. Trial data, dosing, safety, launch.
Once-Monthly Olanzapine Injection: 1st FDA Approval Revealed
The once-monthly olanzapine injection Weltruza gets FDA approval for adults with schizophrenia. Doses, SOLARIS data, safety and launch timing.
Viatris Pacira Acquisition: $1.65B Non-Opioid Pain Deal
Viatris will buy Pacira BioSciences for $36.50 a share in cash, a $1.65 billion deal built on EXPAREL and ZILRETTA. Terms, numbers and risks.
NMC New Guidelines 2026 Ban AI Testimonials, Fake Reviews
NMC guidelines dated 6 Oct 2026 bar fake reviews, guaranteed-cure claims and misleading AI promotion by doctors and hospitals. What is allowed.
Newron FDA Clinical Hold Continues: Evenamide Safety Flag
FDA keeps its hold on Newron US schizophrenia trial, citing a possible cardiac safety signal for evenamide. What is known and what comes next.